Navigation Links
VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
Date:12/14/2010

MOUNTAIN VIEW, Calif., Dec. 14, 2010 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that the company, as part of its continuing effort to secure regulatory approval for QNEXA® in the U.S., submitted a briefing document to the Food and Drug Administration (FDA) designed to address items in the FDA's Complete Response Letter (CRL), issued on October 28, 2010.  The company also announced that the Endocrine and Metabolic Division of the FDA has granted VIVUS a meeting in the second half of January 2011 to discuss the content of the proposed resubmission.

VIVUS is pursuing regulatory approval to market QNEXA (phentermine/topiramate) Controlled Release Capsules in the U.S. for the treatment of obesity, including weight loss and maintenance of weight loss, in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidemia or central adiposity.

"Submission of our briefing document and confirmation of our meeting with the FDA indicate the continued progress VIVUS is making in seeking U.S. approval of QNEXA® for the treatment of obesity," said Leland Wilson, chief executive officer of VIVUS. "We are confident in the data analyses we have compiled in the briefing document, and we look forward to our meeting with the FDA."

About QNEXA Controlled Release Capsules

QNEXA [kyoo-nek-suh] is an investigational drug being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which together decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking QNEXA have demonstrated statistically significant weight loss,
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VIVUS to Present at Two Upcoming Investor Conferences
2. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
3. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
4. VIVUS Announces Sale of MUSE Assets to Meda
5. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
6. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
7. VIVUS to Present at Lazard Capital Markets Healthcare Conference
8. VIVUS Announces Promotion of Peter Tam to President
9. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
10. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
11. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... SHENZHEN, China, Aug. 28, 2014 China ... ("Nepstar" or the "Company"), a leading retail drugstore ... directly operated stores, today announced its unaudited financial ... Financial HighlightsFor the quarter ended June 30, ... RMB686.6 million (US$110.7 million) compared to RMB638.8 million in ...
(Date:8/27/2014)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. , (OTCQB: DMPI), developer of advanced ... company at the 16th Annual Rodman & Renshaw Global ... Co., LLC. The presentation will take place Tuesday, September 9th ... (4th floor) at the New York Palace Hotel in ...
(Date:8/27/2014)... BURLINGTON, Mass. , Aug. 27, 2014 /PRNewswire/ ... six different specialties (medical oncology, hematology-oncology, rheumatology, gastroenterology, ... of clinical trials that a biosimilar has been ... which biosimilar product they choose to prescribe. ... Advisory Service report entitled Acceptance of ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 11DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials 2
(Date:8/28/2014)... Hastings and Hastings, a Phoenix Arizona ... in the industry is pleased to report having saved ... approximately $125,000. This is exciting news for existing clients ... well defined proof that Hastings and Hastings stands behind ... fees. Saving clients money when it comes to settlements ...
(Date:8/28/2014)... 28, 2014 InventHelp, a ... clients, an inventor from California, has designed an alternative ... invention is patented. , The “Abdominal Swimming Support” is ... risk of injuries from physical activity if one is ... or muscular atrophy. Ideal for use as a ...
(Date:8/28/2014)... Baltimore, MD (PRWEB) August 28, 2014 ... has received Diamond level Allergan Privilege Program status ... widely used treatments as Botox, Juvederm, and Voluma. Maryland ... exemplary and prolific use of these treatments. The dermatologists ... in injectable treatments, and are one of the leading ...
(Date:8/28/2014)... 2014 Altec Products, Inc., a ... announced today that they have been awarded the ... of the International Association of Microsoft Channel Partners ... founded in 1994, providing Microsoft Partners with a ... community at large while facilitating mutual growth and ...
(Date:8/28/2014)... 2014 Dr. Bryan McIntosh of Bellevue, ... guide to the tummy tuck cosmetic procedure, leading ... procedure itself, and how to recover well afterwards. ... Dr. McIntosh also discusses how to have accurate expectations ... the procedure is as successful as possible. , To ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $13,750 On A Settlement Of $125,000 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $13,750 On A Settlement Of $125,000 3Health News:InventHelp® Client Patents “Abdominal Swimming Support” – Invention Could Serve as an Alternative Flotation Device 2Health News:Maryland Laser Skin and Vein Receives Diamond Status From Allergan 2Health News:Altec and Bond Consulting Services Receive Award from the International Association of Microsoft Channel Partners SoCal Chapter 2Health News:Altec and Bond Consulting Services Receive Award from the International Association of Microsoft Channel Partners SoCal Chapter 3Health News:The Ultimate Guide to the Tummy Tuck Surgery eBook is Released by Dr. Bryan McIntosh 2
... healthy lifestyle that includes not smoking, limiting alcohol intake, and ... the journal PLoS Medicine , Wei Zheng, M.D., Ph.D., ... results from a large study quantifying the impact of combining ... lifestyle pattern being normal weight, having low belly fat, ...
... study released today by the American Lung Association, and ... helping smokers quit not only saves lives but also ... titled Smoking Cessation: the Economic Benefits, provides a nationwide ... smoking with the economic benefits of states providing cessation ...
... New research findings from the Universit de Montral reveals ... understand and use irony. This study, published recently in ... way parents communicate with their family. "Previous studies ... eight or ten," says Stephanie Alexander, a postdoctoral student ...
... really takes for seniors to make ends meet in each ... state Capitol in Sacramento. The release is ... (Elder Index), a tool that measures the actual costs of ... replacing federal poverty level (FPL) guidelines as a new standard ...
... HealthDay Reporter , TUESDAY, Sept. 14 (HealthDay News) ... when in vitro fertilization is done during the springtime. ... highest in the spring -- 73.5 percent vs. 67.9 ... than the summer and fall rates. "Epidemiolgists have ...
... TUESDAY, Sept. 14 (HealthDay News) -- The risk of tendon ... higher levels of estrogen, a small European study suggests. ... to test estrogen levels in order to identify at-risk athletes ... training program, said Katherine E. Burgess, of the University of ...
Cached Medicine News:Health News:Benefits of healthy lifestyle factors stronger in combination 2Health News:New study finds positive return on investment for states that invest in quit smoking treatments 2Health News:New study finds positive return on investment for states that invest in quit smoking treatments 3Health News:Report shows federal poverty guidelines leave state's seniors destitute 2Health News:Report shows federal poverty guidelines leave state's seniors destitute 3Health News: In Vitro Fertilization Success Rate Higher in Spring, Study Suggests 2Health News: In Vitro Fertilization Success Rate Higher in Spring, Study Suggests 3
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
... 50 analyzer is an ... offices and smaller laboratories ... of state-of-the-art instrument-based testing ... efficient way to obtain ...
... Hemoglobin Test Systems provide ... quantitative hemoglobin results with ... a large hematology analyzer. ... of either the B-Hemoglobin ...
... a qualitative immunoassay for urinary albumin that ... This albumin specific, CLIA Waived test has ... of 95%, and gives accurate results in ... up to 8 hours. Since early detection ...
Medicine Products: